Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...
Hosted on MSN20h
How Chinese biotech firm BGI grew to rival US giant Illumina & enter US-China tariff warChina has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...
Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting ...
Hosted on MSN1d
Top start-up accelerators for tech companies in 2025Top start-up accelerators for tech companies in 2025Issued by Emerging SoftwareJohannesburg, 14 Feb 2025Visit our press officeStart-up accelerators are intensive, short-term programmes designed to ...
"Our AI-powered platform is designed with the goal of transforming the IPO process by making it more efficient and accessible," said Edward C. Lee, CEO of Hestia Insight Inc. Mr. Lee continued, "This ...
South San Francisco has seen leasing and activity in its life sciences real estate market decrease despite a bevy of new ...
Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to ...
DetraPel, Inc., a clean-tech advanced materials company, will relocate its headquarters and advanced manufacturing operations ...
AbbVie and Xilio Therapeutics have inked a collaboration and option-to-license agreement potentially worth more than $2 billion to clinical-stage biotechnology company Xilio.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback